Valuation: Adocia

Market Cap 75.45M 86.33M 69.74M 64.44M 121M 8.29B 124M 832M 326M 4.06B 324M 317M 13.98B P/E 2026 *
15.6x
P/E 2027 * 7.74x
Enterprise Value 45.6M 52.18M 42.16M 38.95M 73.34M 5.01B 74.67M 503M 197M 2.45B 196M 192M 8.45B EV / Sales 2026 *
3.65x
EV / Sales 2027 * 3.27x
Free-Float
90.95%
Yield 2026 *
-
Yield 2027 * -
1 day-22.68%
1 week+23.55%
Current month+17.15%
1 month+14.47%
3 months+12.36%
6 months-21.13%
Current year-25.80%
1 week 3.69
Extreme 3.69
4.89
1 month 3.69
Extreme 3.69
4.89
Current year 3.69
Extreme 3.69
7.45
1 year 3.69
Extreme 3.69
12.24
3 years 3.15
Extreme 3.15
16.16
5 years 2.8
Extreme 2.7967
16.16
10 years 2.8
Extreme 2.7967
61.28
Manager TitleAgeSince
Chief Executive Officer 55 2023-05-10
Director of Finance/CFO - 2024-09-22
Chief Tech/Sci/R&D Officer - 2014-11-30
Director TitleAgeSince
Director/Board Member 55 2013-04-18
Chairman 80 2012-02-23
Director/Board Member 58 2013-06-17
Change 5-day change 1-year change 3-year change Capi.($)
-22.35%+23.55% - - 86.33M
-1.26%-6.03%+56.26%+71.76% 54.49B
+6.05%+7.79%+62.23%+88.46% 55.93B
+0.89%-2.42%+8.07%+434.51% 23.87B
+0.37%-4.13%-18.56%-16.48% 22.86B
+3.66%+11.22%+45.27%-2.91% 20B
+0.74%-1.92%+35.57%-29.14% 17.48B
-4.00%-10.96%+181.91%+328.17% 15.39B
+7.59%+11.60%+49.61%+718.67% 15.19B
-0.48%-2.30%+22.36%+187.62% 14.02B
Average -0.93%-1.83%+49.19%+197.85% 26.58B
Weighted average by Cap. +1.79%-0.49%+48.94%+154.18%

Financials

2026 *2027 *
Net sales 12.5M 14.3M 11.56M 10.68M 20.1M 1.37B 20.47M 138M 54.07M 673M 53.73M 52.54M 2.32B 32.26M 36.91M 29.82M 27.55M 51.88M 3.55B 52.82M 356M 140M 1.74B 139M 136M 5.98B
Net income -518K -593K -479K -442K -833K -56.92M -848K -5.71M -2.24M -27.87M -2.23M -2.18M -95.97M -47.3M -54.13M -43.73M -40.4M -76.08M -5.2B -77.46M -521M -205M -2.55B -203M -199M -8.77B
Net Debt -29.84M -34.15M -27.59M -25.49M -48M -3.28B -48.87M -329M -129M -1.61B -128M -125M -5.53B 30.18M 34.53M 27.9M 25.77M 48.53M 3.32B 49.41M 333M 131M 1.62B 130M 127M 5.59B
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
73
Date Price Change Volume
25-05-15 4.890 -8.86% 2,399
26-07-14 €3.784 +2.55% 1,000
26-07-13 €3.690 -3.20% 21
26-07-10 €3.812 -0.94% 457
26-07-09 €3.848 +1.05% 1,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.856EUR
Average target price
10.70EUR
Spread / Average Target
+177.49%

Quarterly revenue - Rate of surprise